MIM
RPRX icon

MetLife Investment Management’s Royalty Pharma RPRX Stock Holding History

MetLife Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379K Buy
6,752
+450
+7% +$23.4K ﹤0.01% 2078
2026
Q1 		$302K Sell
6,302
-65
-1% -$2.85K ﹤0.01% 1992
2025
Q4 		$246K Buy
6,367
+44
+0.7% +$1.68K ﹤0.01% 2175
2025
Q3 		$223K Sell
6,323
-174
-3% -$6.3K ﹤0.01% 2256
2025
Q2 		$234K Sell
6,497
-435
-6% -$14.4K ﹤0.01% 2109
2025
Q1 		$216K Buy
6,932
+57
+0.8% +$1.81K ﹤0.01% 2157
2024
Q4 		$175K Buy
6,875
+19
+0.3% +$504 ﹤0.01% 2361
2024
Q3 		$194K Sell
6,856
-154
-2% -$4.27K ﹤0.01% 2305
2024
Q2 		$185K Sell
7,010
-234
-3% -$6.49K ﹤0.01% 2304
2024
Q1 		$220K Buy
7,244
+17
+0.2% +$501 ﹤0.01% 2148
2023
Q4 		$203K Sell
7,227
-138
-2% -$3.79K ﹤0.01% 2236
2023
Q3 		$200K Buy
7,365
+10
+0.1% +$297 ﹤0.01% 2207
2023
Q2 		$226K Sell
7,355
-349
-5% -$11.8K ﹤0.01% 2192
2023
Q1 		$278K Buy
7,704
+17
+0.2% +$630 ﹤0.01% 2015
2022
Q4 		$304K Buy
7,687
+137
+2% +$5.72K ﹤0.01% 1981
2022
Q3 		$303K Sell
7,550
-183
-2% -$7.82K ﹤0.01% 2014
2022
Q2 		$325K Sell
7,733
-7,378
-49% -$302K ﹤0.01% 1967
2022
Q1 		$589K Buy
+15,111
New +$593K ﹤0.01% 1670

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's RPRX Position: Q2 2026 in Review

MetLife Investment Management increased its Royalty Pharma (RPRX) stake by 7.1% in Q2 2026, buying an estimated $23.4K and bringing the position to 6,752 shares worth $379K. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

MetLife Investment Management first reported a position in RPRX in Q1 2022 and has held it in 18 quarters since. The position peaked at $589K in Q1 2022. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • MetLife Investment Management held 6,752 shares of Royalty Pharma worth $379K as of Q2 2026.
  • MetLife Investment Management bought 450 Royalty Pharma shares in Q2 2026, an estimated $23.4K.
  • Royalty Pharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2078 holding.
  • MetLife Investment Management first reported a position in Royalty Pharma in Q1 2022 and has held it in 18 quarters since.
  • MetLife Investment Management's Royalty Pharma position peaked at $589K in Q1 2022.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.